Pfizer Wins a Big One in Britain

A court rejects Ranbaxy's patent challenge to Lipitor, forestalling a generic version of the blockbuster. Next: A similar battle in the U.S.

Pfizer (PFE) investors are breathing easier. On Oct. 12, a British court handed the drugmaker a big victory, rejecting an effort by generic-drug maker Ranbaxy Laboratories to launch a generic version of Lipitor, Pfizer's $12.5 billion blockbuster cholesterol-lowering drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.